Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction
Telomir Pharmaceuticals (NASDAQ:TELO) has announced groundbreaking preclinical data showing that its lead compound Telomir-1 effectively inhibits three key histone demethylase enzymes: JMJD3, FBXL10, and FBXL11. These enzymes are crucial regulators of gene expression and are implicated in various diseases.
The study, conducted with Eurofins Discovery, demonstrates Telomir-1's potential to treat multiple conditions through epigenetic modulation, including cancer, autoimmune disorders, neurodegeneration, and metabolic dysfunction. The compound has shown superior performance compared to Paclitaxel and Rapamycin in preclinical cancer models, particularly in reactivating tumor suppressor genes.
The company is advancing Telomir-1's development and plans to finalize its first IND-enabling program, marking a significant step toward clinical trials.
Telomir Pharmaceuticals (NASDAQ:TELO) ha annunciato dati preclinici rivoluzionari che dimostrano come il suo composto principale, Telomir-1, inibisca efficacemente tre enzimi chiave della demetilasi degli istoni: JMJD3, FBXL10 e FBXL11. Questi enzimi sono regolatori fondamentali dell'espressione genica e sono coinvolti in diverse patologie.
Lo studio, condotto in collaborazione con Eurofins Discovery, evidenzia il potenziale di Telomir-1 nel trattamento di molteplici condizioni attraverso la modulazione epigenetica, tra cui cancro, malattie autoimmuni, neurodegenerazione e disfunzioni metaboliche. Il composto ha mostrato prestazioni superiori rispetto a Paclitaxel e Rapamicina in modelli preclinici di cancro, soprattutto nella riattivazione dei geni oncosoppressori.
L'azienda sta portando avanti lo sviluppo di Telomir-1 e prevede di completare il primo programma di abilitazione IND, segnando un passo importante verso le sperimentazioni cliniche.
Telomir Pharmaceuticals (NASDAQ:TELO) ha anunciado datos preclínicos innovadores que muestran que su compuesto principal, Telomir-1, inhibe eficazmente tres enzimas clave de la histona desmetilasa: JMJD3, FBXL10 y FBXL11. Estas enzimas son reguladores esenciales de la expresión génica y están implicadas en diversas enfermedades.
El estudio, realizado con Eurofins Discovery, demuestra el potencial de Telomir-1 para tratar múltiples condiciones mediante la modulación epigenética, incluyendo cáncer, trastornos autoinmunes, neurodegeneración y disfunciones metabólicas. El compuesto ha mostrado un rendimiento superior en comparación con Paclitaxel y Rapamicina en modelos preclínicos de cáncer, especialmente en la reactivación de genes supresores de tumores.
La compañía está avanzando en el desarrollo de Telomir-1 y planea finalizar su primer programa de habilitación IND, marcando un paso importante hacia los ensayos clínicos.
Telomir Pharmaceuticals (NASDAQ:TELO)는 주요 화합물인 Telomir-1이 세 가지 핵심 히스톤 디메틸라제 효소인 JMJD3, FBXL10, FBXL11을 효과적으로 억제한다는 획기적인 전임상 데이터를 발표했습니다. 이 효소들은 유전자 발현의 중요한 조절자이며 여러 질병과 관련이 있습니다.
Eurofins Discovery와 함께 진행된 이번 연구는 Telomir-1이 암, 자가면역 질환, 신경퇴행성 질환, 대사 장애 등 다양한 질환을 후생유전학적 조절을 통해 치료할 잠재력을 보여줍니다. 이 화합물은 전임상 암 모델에서 Paclitaxel과 Rapamycin보다 뛰어난 성능을 보였으며, 특히 종양 억제 유전자의 재활성화에 효과적이었습니다.
회사는 Telomir-1의 개발을 진행 중이며, 첫 번째 IND 승인 프로그램을 마무리할 계획으로 임상 시험에 한 걸음 더 다가서고 있습니다.
Telomir Pharmaceuticals (NASDAQ:TELO) a annoncé des données précliniques révolutionnaires montrant que son composé principal, Telomir-1, inhibe efficacement trois enzymes clés de la déméthylase des histones : JMJD3, FBXL10 et FBXL11. Ces enzymes sont des régulateurs essentiels de l'expression génétique et sont impliquées dans diverses maladies.
L'étude, réalisée en collaboration avec Eurofins Discovery, démontre le potentiel de Telomir-1 pour traiter plusieurs affections par modulation épigénétique, notamment le cancer, les troubles auto-immuns, la neurodégénérescence et les dysfonctionnements métaboliques. Le composé a montré une performance supérieure à celle du Paclitaxel et du Rapamycine dans des modèles précliniques de cancer, en particulier pour la réactivation des gènes suppresseurs de tumeurs.
L'entreprise poursuit le développement de Telomir-1 et prévoit de finaliser son premier programme d'autorisation IND, marquant une étape importante vers les essais cliniques.
Telomir Pharmaceuticals (NASDAQ:TELO) hat bahnbrechende präklinische Daten veröffentlicht, die zeigen, dass seine Leitverbindung Telomir-1 drei wichtige Histon-Demethylase-Enzyme – JMJD3, FBXL10 und FBXL11 – effektiv hemmt. Diese Enzyme sind entscheidende Regulatoren der Genexpression und stehen im Zusammenhang mit verschiedenen Krankheiten.
Die Studie, durchgeführt in Zusammenarbeit mit Eurofins Discovery, zeigt das Potenzial von Telomir-1, durch epigenetische Modulation mehrere Erkrankungen zu behandeln, darunter Krebs, Autoimmunerkrankungen, Neurodegeneration und metabolische Dysfunktionen. Die Verbindung zeigte in präklinischen Krebsmodellen eine überlegene Leistung im Vergleich zu Paclitaxel und Rapamycin, insbesondere bei der Reaktivierung von Tumorsuppressorgenen.
Das Unternehmen treibt die Entwicklung von Telomir-1 voran und plant, sein erstes IND-fähiges Programm abzuschließen, was einen bedeutenden Schritt in Richtung klinischer Studien darstellt.
- Discovery of Telomir-1's ability to inhibit three previously 'undruggable' histone demethylase enzymes
- Superior performance compared to Paclitaxel and Rapamycin in preclinical cancer models
- Broad therapeutic potential across multiple high-value disease areas
- Successful reactivation of key tumor suppressor genes in PC3 xenograft studies
- Still in preclinical stage with no human trial data yet
- Requires further validation studies to confirm mechanism of action
- Complex mechanism of action may present regulatory challenges
- Multiple competing therapeutic areas could complicate development strategy
Insights
Telomir-1 shows promising preclinical data targeting previously "undruggable" epigenetic enzymes, potentially addressing multiple disease pathways simultaneously.
Telomir Pharmaceuticals has unveiled significant in vitro data demonstrating that their lead compound, Telomir-1, inhibits three critical histone demethylase enzymes: JMJD3, FBXL10, and FBXL11. This finding is particularly notable because these enzymes have been considered largely undruggable despite their well-established roles in disease progression.
The mechanism revealed here represents a potentially elegant approach to disease intervention. By targeting these epigenetic regulators, Telomir-1 could reactivate silenced tumor suppressor genes while simultaneously silencing disease-promoting genes. This dual action creates a more comprehensive intervention than many single-target approaches.
What makes this especially intriguing is the multi-disease potential. The same epigenetic dysregulation that drives cancer progression also contributes to autoimmune disorders, neurodegeneration, and metabolic dysfunction. Drugs that can normalize these pathways could theoretically address multiple conditions with a single compound – a holy grail in drug development.
The preclinical data suggests Telomir-1 outperformed both Paclitaxel (standard chemotherapy) and Rapamycin in reactivating STAT1, a critical tumor suppressor gene, in prostate cancer models. This comparative efficacy data provides an important benchmark against established treatments.
However, we must recognize these are early-stage findings. The transition from in vitro results to clinical applications faces significant hurdles, and many promising preclinical compounds fail to demonstrate similar efficacy in humans. Telomir has not yet entered IND-enabling studies, placing them likely 1-2 years from potential human trials.
The announcement from Telomir represents a meaningful advance in understanding their lead compound's mechanism of action. What stands out is Telomir-1's ability to inhibit three distinct epigenetic targets simultaneously – a polypharmacological profile that could potentially offer advantages over single-target approaches currently dominating development pipelines.
From a market perspective, the multi-indication potential significantly expands Telomir's addressable market. Rather than being limited to a single disease, the company could pursue several high-value therapeutic areas including oncology, autoimmune disorders, neurodegeneration, and metabolic diseases. This diversification reduces clinical development risk and potentially increases partnership opportunities.
The comparative data showing Telomir-1 outperforming established treatments like Paclitaxel and Rapamycin in certain preclinical models provides an important benchmark, suggesting potential for differentiation in a crowded market. Notably, these are well-established treatments, setting a high bar for comparison.
The company's focus on epigenetic regulation positions them in a rapidly growing field that has produced successful drugs like DNA methyltransferase inhibitors and HDAC inhibitors, though histone demethylases have proven more challenging to target successfully. If Telomir-1 can effectively modulate these targets with acceptable safety, it could address a significant unmet need.
However, as a preclinical-stage asset that hasn't yet begun IND-enabling studies, Telomir-1 faces substantial development risks and a lengthy timeline before potential commercialization. The complexity of simultaneously targeting multiple enzymes may create challenges in optimizing dosing and managing potential off-target effects in future clinical studies.
New data from Eurofins Discovery show that Telomir-1 blocks enzymes that drive disease by turning off critical genes-highlighting its potential to treat cancer, autoimmune conditions, neurodegeneration, and metabolic disorders through epigenetic modulation.
MIAMI, FL / ACCESS Newswire / August 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company developing therapies that target the underlying mechanisms of aging and age-related diseases, today announced new preclinical data revealing that Telomir-1 potently inhibits three key histone demethylase enzymes-JMJD3, FBXL10, and FBXL11-that regulate gene expression through epigenetic mechanisms. These enzymes are known to influence tumor progression, immune response, metabolic function, and neuroinflammation.
The study, conducted in collaboration with Eurofins Discovery, provides further clarity on Telomir-1's mechanism of action and supports its continued development as a disease-modifying candidate across multiple therapeutic areas. Histone demethylases are upstream regulators of epigenetic silencing and activation. Overactivation of these enzymes can result from genetic amplification, chronic inflammation, or stress signals from the tumor microenvironment. These factors can lead to persistent gene silencing or inappropriate activation of disease-driving genes-contributing directly to tumor growth, immune dysfunction, metabolic imbalance, and neuroinflammation.
Key Epigenetic Targets Inhibited by Telomir-1:
FBXL11 (KDM2A)
A key regulator of gene expression, FBXL11 is overactive in several major cancers-including lung, gastric, and ovarian-where it helps tumors grow and avoid immune detection. It has also been linked to conditions like autism and impaired glucose control, highlighting its broader role in disease.FBXL10 (KDM2B)
A well-known driver of aggressive cancers like leukemia, breast, and pancreatic, FBXL10 enables tumors to resist treatment and maintain stem-like characteristics that fuel growth and recurrence. It also plays a role in metabolic and inflammatory pathways, making it a high-value target for therapies aiming to disrupt the root mechanisms of disease.JMJD3 (KDM6B)
A central regulator of inflammation and tumor progression, JMJD3 is overexpressed in several aggressive cancers-including prostate, glioma, and ovarian-where it promotes metastasis and immune dysfunction. It also plays a key role in chronic inflammatory, auto-immune and neurodegenerative diseases like lupus and Alzheimer's, through activation of cytokines such as IL-6 and IL-4, making it a high-priority epigenetic target.
These three targets are among the most validated histone demethylases in disease biology but have remained largely undruggable until now. Telomir-1's ability to inhibit all three reinforces its potential as a broadly applicable therapeutic candidate.
"This may be one of the most important mechanistic discoveries in Telomir-1's development," said Erez Aminov, CEO of Telomir. "If confirmed through further studies, it could position Telomir-1 as a breakthrough in the effort to address the root causes of age-related diseases."
"Targeting histone demethylases has long been considered undruggable," said Dr. Itzchak Angel, Chief Scientific Advisor at Telomir. "These findings demonstrate that Telomir-1 can modulate epigenetic machinery in several distinct, but functionally related sites that can work in concert to achieve synergic effects. It opens new therapeutic avenues for diseases where gene silencing drives pathology."
Broad Therapeutic Potential of Telomir-1
Cancer: By reactivating tumor suppressor genes and silencing cancer-driving genes like c-Myc and CDK6, Telomir-1 may help slow tumor growth, improve treatment response, and complement both chemotherapy and immunotherapy strategies.
Inflammatory & Autoimmune Disorders: Telomir-1 may reduce overactive immune responses by turning down key inflammatory signals, with possible applications in conditions like lupus, rheumatoid arthritis, and other autoimmune diseases.
Neurodegeneration & Neurodevelopment: By restoring balance to brain-related gene networks, Telomir-1 could impact disorders such as Alzheimer's disease and autism, where inflammation and gene misregulation play a role.
Metabolic Dysfunction: Telomir-1's ability to influence genes involved in fat storage, insulin response, and glucose control suggests potential in treating diseases like type 2 diabetes.
By targeting this epigenetic machinery-including histone demethylation and associated DNA methylation pathways-Telomir-1 may unlock therapeutic benefits across diseases marked by gene silencing.
Advancing Toward the Clinic
These new data build upon previously reported findings demonstrating that Telomir-1 reverses epigenetic gene silencing in aggressive prostate cancer models, specifically reactivating key tumor suppressors like STAT1 and TMS1 in PC3 xenograft studies. In head-to-head preclinical comparisons, Telomir-1 outperformed both Paclitaxel (a standard chemotherapy) and Rapamycin in reactivating STAT1-delivering more complete demethylation and stronger expression of this critical tumor suppressor gene.
These findings provide functional validation of Telomir-1's mechanism and reinforce its potential to complement or surpass existing treatment options in epigenetically driven cancers. The company is continuing preclinical development of Telomir-1 across oncology and other high-burden indications, with plans to finalize its first IND-enabling program.
For more information, visit www.telomirpharma.com
Cautionary Note Regarding Forward-Looking Statements
This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.
Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact Information
Helga Moya
info@telomirpharma.com
(786) 396-6723
SOURCE: Telomir Pharmaceuticals, Inc
View the original press release on ACCESS Newswire
FAQ
What are the key enzymes that Telomir-1 (TELO) inhibits according to the new data?
How does Telomir-1's performance compare to existing cancer treatments in preclinical studies?
What diseases could potentially be treated with Telomir-1 based on the new findings?
What is the current development stage of Telomir-1?
How does Telomir-1's mechanism of action work in cancer treatment?
